tiprankstipranks
Cocrystal Pharma’s Promising Antiviral Candidate for Influenza A
Company Announcements

Cocrystal Pharma’s Promising Antiviral Candidate for Influenza A

Don't Miss our Black Friday Offers:

An update from Cocrystal Pharma (COCP) is now available.

Cocrystal Pharma, Inc. recently shared exciting news about their CC-42344 product candidate, which shows promise as an antiviral treatment for both pandemic and seasonal influenza A. This update could be a game-changer for investors looking for potential growth opportunities in the biopharmaceutical sector.

Learn more about COCP stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyCocrystal Pharma reports Q3 EPS (49c), consensus (57c)
Brian AndersonCocrystal Pharma (COCP) Q3 Earnings Cheat Sheet
TipRanks Auto-Generated NewsdeskCocrystal Pharma Advances Antiviral Drug Development
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App